（编辑 姚尧） 证券日报网讯 8月12日晚间，塞力医疗发布公告称，公司于近日收到实际控制人温伟先生的通知，温伟 先生将前期质押给北京湘钢钢铁材料销售有限公司的3，000，000股股份全部办理完成了解除质押业 务。 ...

截至发稿，塞力医疗市值为56亿元。 每经头条（nbdtoutiao）——未收车就要结清20多万元尾款，否则5000元定金作废？小米汽车知情人 士：涉及两种特殊情况；律师解读→ （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，塞力医疗（SH 603716，收盘价：29.18元）8月12日晚间发布公告称，塞力斯医疗科技集 团股份有限公司控股股东赛海（上海）健康科技有限公司持有公司约2164万股无限售条件流通股股票， 占公司总股本的11.33%。赛海科技累计质押公司股份1400万股，占其持有公司股份比例为64.69%，占 公司总股本比例为7.33%。 公司实际控制人温伟先生持有公司股份约963万股，占公司总股本比例为5.04%。近日，温伟先生将其 中300万股股份办理完成了解除质押登记手续，本次解除质押手续办理完毕后，温伟先生累计质押公司 股份530万股，占其持有公司股份比例为55.01%，占公司总股本比例为2.77% 。截至本公告披露日，公司控股股东赛海科技及实际控制人温伟先生累计质押公司股份数为1930万股， 占其合计持有公司股份比例为61. ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-069 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于"塞力转债"付息公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 塞力斯医疗科技集团股份有限公司（以下简称"公司"）2020 年 8 月 21 日 公开发行的可转换公司债券（以下简称"本期债券"）将于 2025 年 8 月 21 日支 付自 2024 年 8 月 21 日至 2025 年 8 月 20 日期间的利息。根据公司《公开发行可 转换公司债券募集说明书》（以下简称"《募集说明书》"）及《公开发行可转 换公司债券上市公告书》（以下简称"《上市公告书》"）有关条款的规定，现 将有关事项公告如下： | 债券名称 | 塞力斯医疗科技集团股份有限公司可转换公司债券 | | --- | --- | | 债券简称 | 塞力转债 | | 债券代码 | 113601 | | 债券类型 | 可转换为 ...

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）控股股东赛海 （上海）健康科技有限公司（以下简称"赛海科技"）持有公司 21,642,540 股 无限售条件流通股股票，占公司总股本的 11.33%（截至 2025 年 6 月 30 日总股 本，下同）。赛海科技累计质押公司股份 14,000,000 股，占其持有公司股份比 例为 64.69%，占公司总股本比例为 7.33%。 公司实际控制人温伟先生持有公司股份 9,634,208 股，占公司总股本比 例为 5.04%。近日，温伟先生将其中 3,000,000 股股份办理完成了解除质押登记 手续，本次解除质押手续办理完毕后，温伟先生累计质押公司股份 5,300,000 股，占其 ...

证券之星消息，8月12日医药商业板块较上一交易日下跌0.28%，塞力医疗领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 26.39 | 4.31% | 13.85万 | | 3.60亿 | | 301408 | 华人健康 | 15.38 | 0.72% | 19.09万 | | 2.94亿 | | 002788 | 醫症医药 | 8.76 | 0.46% | 7.10万 | | 6226.18万 | | 000078 | 海王生物 | 2.73 | 0.37% | 54.67万 | | 1.51亿 | | 603368 | 柳药集团 | 18.35 | 0.22% | 8.06万 | | 1.48亿 | | 600713 | 南京医药 | 5.27 | 0.19% | 10.26万 | | 5411.55万 | | ...

Group 1 - The SPD concept is gaining traction in the secondary market, with companies like Seli Medical, Guoke Hengtai, and Chongyao Holdings seeing significant stock price increases [1] - SPD stands for Supply, Processing, and Distribution, representing a modern supply chain management model in healthcare [1] - SPD business involves operators signing contracts with medical institutions to centralize the supply, inventory, processing, and distribution of medical materials [1] Group 2 - The SPD model allows companies to build smart supply chain management platforms for medical institutions, providing diversified services to enhance operational efficiency [1] - The introduction of lean management in SPD can reduce waste, optimize processes, and lower procurement costs for medical institutions [1] - The analyst predicts a substantial market demand for SPD in Chinese hospitals due to the rising costs of medical supplies, which account for 50% to 55% of hospital expenses [2] Group 3 - Companies are actively responding to the growing interest in SPD and hospital information technology on investor platforms [2] - Seli Medical claims a significant market share in SPD projects and aims to expand through regional cooperation [2] - Chongyao Holdings has implemented around 80 SPD projects across 14 provinces, serving nearly 70 medical institutions [2]

Company Overview - As of August 8, 2025, the stock price of Sely Medical is reported at 27.60 yuan, reflecting an increase of 0.73% from the previous trading day [1] - The company operates in the pharmaceutical commercial sector, focusing on medical testing centralized services and the research, production, and sales of in vitro diagnostic products [1] - Sely Medical's product range includes biochemistry, immunology, and molecular diagnostics, with business operations extending across multiple regions, including Hubei [1] Stock Performance - During the trading session on August 8, Sely Medical's stock exhibited significant volatility, with a morning rebound at 9:35 AM leading to a rise of over 2% within five minutes, followed by a quick pullback at 9:44 AM with a drop exceeding 2% [1] - The stock's opening price was 27.11 yuan, reaching a high of 28.40 yuan and a low of 26.20 yuan, resulting in a trading range of 8.03% [1] - The total trading volume for the day amounted to 9.85 billion yuan [1] Capital Flow - On August 8, the net inflow of main funds was 33.17 million yuan, accounting for 0.63% of the circulating market value [1] - However, over the past five trading days, the overall trend for main funds has shown a net outflow of 456 million yuan, which represents 8.65% of the circulating market value [1]

Core Insights - The precision medicine sector experienced a slight increase of 0.62% on August 7, with a net outflow of main capital amounting to 93.50 million yuan [1] - A total of 23 stocks within the sector saw gains, while another 23 stocks faced declines [1] Capital Flow Analysis - The companies with the highest net outflows were: - Qianhong Pharmaceutical: 187 million yuan - Saily Medical: 139 million yuan - Zhifei Biological: 134 million yuan - Betta Pharmaceuticals: 104 million yuan - Junshi Biosciences-U: 78.25 million yuan [1] Notable Stock Performances - The following companies showed significant net inflows: - Berry Genomics: 207 million yuan, with a price increase of 5.26% - Lide Man: 158 million yuan, with a price increase of 20.02% - Kehua Bio: 143 million yuan, with a price increase of 9.96% - Da'an Gene: 60.09 million yuan, with a price increase of 2.98% - Sanbo Brain Science: 57.30 million yuan, with a price increase of 5.12% [1]

Company Overview - Sely Medical's stock price showed volatility on August 7, closing at 27.40 yuan, down 2.32% from the previous trading day [1] - The opening price was 27.77 yuan, with a high of 29.32 yuan and a low of 27.22 yuan, resulting in an intraday fluctuation of 7.49% [1] - The company operates in the pharmaceutical commercial sector, focusing on the research, production, and sales of medical devices, including in vitro diagnostic reagents and medical equipment [1] Financial Performance - On August 7, the net outflow of main funds was 139 million yuan, accounting for 2.66% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 465 million yuan, representing 8.89% of the circulating market value [1] - The trading volume for the day was 443,300 hands, with a total transaction amount of 1.247 billion yuan [1]

Core Insights - The DRG/DIP concept increased by 1.00%, ranking 10th among concept sectors, with 11 stocks rising, including Jiarun Technology which hit a 20% limit up [1] - Major gainers in the sector included Jiahe Meikang, Wanda Information, and Taiji Co., with respective increases of 3.68%, 3.08%, and 2.98% [1] - The sector experienced a net outflow of 229 million yuan, with 10 stocks seeing net inflows, and Wanda Information leading with a net inflow of 65.92 million yuan [2][3] Sector Performance - The top-performing concept sectors included Rare Earth Permanent Magnet (+3.24%), Brain-Computer Interface (+2.69%), and Hyperbaric Oxygen Chamber (+2.56%), while the weight-loss drug sector saw a decline of -1.70% [2] - The DRG/DIP concept had a net inflow ratio led by Wanda Information at 10.09%, followed by ST Yilianzhong at 5.78% and Taiji Co. at 4.82% [3][4] Stock Specifics - Key stocks in the DRG/DIP concept included: - Wanda Information: +3.08%, net inflow of 65.92 million yuan, turnover rate of 5.34% [3] - Weining Health: +1.72%, net inflow of 62.81 million yuan, turnover rate of 6.37% [3] - Taiji Co.: +2.98%, net inflow of 42.14 million yuan, turnover rate of 5.36% [3] - Notable declines were seen in stocks like Maidi Technology (-2.61%) and Seli Medical (-2.32%), with significant net outflows [4]